1-year progression free incidence of 84%. Pattern of failure analysis revealed two-mechanisms—one of recurrence in bone adjacent to previously treated site and the other of recurrence in epidural space adjacent to the spinal cord.
Study design included phase-2 and phase-3 components.
Phase 2 component demonstrated feasibility and safety of SABR in large multi-institutional trial. Phase-3 component intends to assess pain relief and quality of life.
Critical review of 31 studies using SABR for spinal metastases.
1 year LC rates consistently above 90%. Additional benefits include the feasibility of use in previously irradiated patients, excellent spinal cord sparing and can also be used after decompressive surgery.
SABR: stereotactic ablative body radiotherapy; LC: local control.